Open Letter from Biopharmaceutical R&D Leaders to the Biden Administration: Your Policies Are Undermining the Cancer Moonshot

America’s biopharmaceutical companies share President Biden’s commitment to eradicating cancer. With more than 1,300 medicines in the research pipeline, the science has never been more promising. But as industry research and development leaders warn in a letter to the Biden Administration, the Cancer Moonshot might have to call off its mission before it can get off the ground.